Pharmidex are delighted to be one of sixteen partners in an EU Horizon 2020 grant - HeatNMof
April 12, 2022

HeatNMof is a heating-triggered drug release from nanometric metal-organic framework composites

The Initial Training Network HeatNMof aims to develop high quality training opportunities for 12 early-stage-researchers (ESRs) in the area of materials science, advanced characterization and biomedicine.


HeatNMof is training the next generation of materials scientists in nanomedicine to exploit heat-triggered release for delivery of anti-tumour drugs. The network is focusing on one of the most promising classes of nanocomposite carriers, inorganic nanoparticles (iNPs) associated to nanoscaled metal organic frameworks (nanoMOFs).


The successful development of this project, involving seven academic, three industrial partners, six partner organisations (5 universities and 1 company), will contribute to the improvement of the highly societal relevant cancer therapy..


Partners: Fundación IMDEA Energía (Coordinator), Universidad de Santiago de Compostela; Centre National de la Recherche Scientifique; Universiteit Antwerpen; Immaterial Labs Ltd; Institut National des Sciences Appliquees de Toulouse; Universitaet Hamburg; Fondazione Istituto Italiano di Tecnologia.; Nanoscale Biomagnetics SL; Isern Patentes Y Marcas M SL.


- Partner Organisations: Universidad Rey Juan Carlos; Universidad de Zaragoza, University of Cambridge; Universite de Nantes; Universita Degli Studi di Genova; Pharmidex.


Funding Institution/Program: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement Nº 860942.


Call: H2020-MSCA-ITN-2019 (ETN)


https://www.energy.imdea.org/research/projects/heatnmof

February 19, 2026
Science is serious… but Pancake Day is not. Yesterday we took a short pause from studies, data and reports to enjoy some well-earned pancakes together as a team. With Ramadan also beginning, we made sure there were plenty saved for colleagues breaking their fast later in the evening. At Pharmidex , we’re proud of the work we deliver, but we’re equally proud of the people behind it. Small moments like this remind us that strong teams are built not only in the lab, but around the table too. Thank you to everyone for your hard work and for making our culture what it is. 🙌
February 17, 2026
We’re proud to announce that Pharmidex has joined the Good Clinical Practice (GCP) Network , a global collaboration advancing ICH-GCP excellence in clinical research. For us, quality and data integrity are not box-ticking exercises, they are fundamental to credible science and responsible drug development. From pre-clinical research through to clinical delivery, we are committed to: • Regulatory rigour • Ethical conduct • Participant protection • Scientifically robust data Joining the GCP Network further strengthens that commitment. We look forward to contributing to a global community dedicated to raising the bar across clinical research.
February 12, 2026
Pharmidex now offers integrated in vivo CAR-T study support , combining robust in-life pharmacology with advanced f low cytometry –based cellular analysis. We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner. Let’s talk. 🌐 www.pharmidex.com
More Posts